E4NA.F AROVELLA THERAPEUTICS

Healthcare Biotechnology Frankfurt Exchange
0.0280 EUR
Close of Nov 11, 2026
0.0260 0.0560
Market cap
EUR 33.8M
P/E
-
P/B
3.81x
ROE
-48.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is E4NA.F undervalued?

Graham number

The Graham number of AROVELLA THERAPEUTICS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AROVELLA THERAPEUTICS fundamental analysis

No fundamental analysis for AROVELLA THERAPEUTICS yet.

AROVELLA THERAPEUTICS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AROVELLA THERAPEUTICS

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer…

Full company profile